This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
Best wishes.
I go to the hepatology group at University of Colorado Hospital. They are supposed to be among the best in the country.
Your dad's AFP is 9. So in his case the AFP is not indicating HCC. AFP is not a true measure of HCC. It is only a marker. It suggestive but not diagnostic of HCC. An AFP of 500+ or quickly raising AFP number are what is usually looked for as indication of HCC. Luckily your father is getting his liver scans every cirrhotic should and it could be seen in the scan.
You say his cancer is untreatable but if it hasn't spread outside of the liver HCC could put him near the front of the transplant list. Does your father have a relationship with a nearby transplant center? If not, please speak to the 2nd opinion doctor this.
Tell your father not to worry or blame himself about missing his injection. It had nothing to do with the HCC. As everyone said according to The HALT-C study who's results were released last November, maintenance therapy has no benefit in preventing the rates of HCC unfortunaetly. Talk to your 2nd opinion doctor and he will confirm this. This was big news. Many docs and patients were hoping it might be a way to stop the advancement of fibrosis and the risk of HCC in cirrhotic patients.
"The HALT-C trial unequivocally demonstrated that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C and a program director for the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These results add to the incentive to develop more effective drugs that will benefit patients with severe liver disease due to hepatitis C."
HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, assessed whether long-term treatment with peginterferon alfa-2a reduced the development of cirrhosis, liver failure, or liver cancer. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in weekly injections for 3.5 years. The 533 patients in the control arm underwent the same follow-up and care as the treated patients including liver biopsies, quarterly clinic visits, and blood tests. All patients had advanced liver fibrosis, a gradual scarring of the liver that puts patients at risk for progressive liver disease.
The outcomes assessed in HALT-C were death, liver cancer, ascites (excess fluid in the abdomen), or encephalopathy (brain and nervous system damage), and for those who did not have cirrhosis initially, the development of cirrhosis. At the end of the study, 34.1 percent of the patients in the treated group and 33.8 percent of the patients in the control group had experienced at least one outcome. Patients in the treated group had significantly lower blood levels of the hepatitis C virus and less liver inflammation. However, there was no major difference in rates of any of the primary outcomes between groups."
Take care and let us know how your dad is doing and what you learn from getting a second opinion. Best of luck to you and your family.
Hector
As far as the quick growth of the tumor (.6 cm to 1.6 cm), it's my understanding that HCC doubling time can be anywhere from 2-12 months (IMHO, pretty fast). But, what, if I may ask, led your father's doctors to diagnose HCC? (As Hector mentions above, his AFP is considered "in-range" -- did they do other/more testing?) In my husband's case, we insist on